Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.

Fiche publication


Date publication

janvier 2019

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MARCHINI Antonio, Dr DAEFFLER Laurent


Tous les auteurs :
Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J

Résumé

Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a "cold" immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.

Mots clés

H-1PV, checkpoint blockade, combination therapy, immunogenic cell death, immunotherapy, oncolytic viruses, tumor microenvironment

Référence

Front Immunol. 2019 ;10:1848